Identification of resistance mechanisms to EGFR treatment in the real world using a clinicogenomic database Published April 2018 Citation Singal, G, Li, G, Agarwala, V, Kaushik, G, O’Connell, C, Alpha-CobbG, Caron, T, Bourque, D, Guria, A, Frank, S, Frampton, G, Carson, K, Abernethy, A.P., Miller, V.A. . AACR Annual Meeting. . https://4076230.fs1.hubspotusercontent-na1.net/hubfs/4076230/flatiron-com-pdf/AACR-2018-FH-FMI-CGDB-Poster-180411.pdf Authors: Sources:American Association for Cancer Research Annual Meeting Share Posted inPublicationsDrug discovery More publicationsWorld Conference on Lung CancerAugust 2025Disease burden and rwPFS as a surrogate endpoint for rwOS in NTRK+ NSCLC and other advanced/metastatic solid tumorFlores Avile C, Su I-H, Huang P-C, Cho-Phan C, Camidge R, Yuan Y.Publication summaryPublicationsNon-small cell lung cancerWorld Conference on Lung CancerAugust 2025Evolving treatment patterns in early-stage non-small cell lung cancer in the USGray J E, Thoele K, Gilligan A M, et al.Publication summaryPublicationsTreatment patternsNon-small cell lung cancerWorld Conference on Lung CancerAugust 2025Real-world biomarker testing and treatment initiation in patients with resected early-stage NSCLC (eNSCLC) in the US and UKRinaldi C, Halloran S, Pittel H, et al.Publication summaryPublicationsTreatment patternsNon-small cell lung cancer